Cervix Cancer Clinical Trial
Official title:
To Assess the Feasibility and Impact of Computed Tomotherapy (CT) and Magnetic Resonance Imaging (MRI) Fusion on Radiation Treatment Planning for Ten Patients With Cancer of the Cervix
Patients with more advanced stages of cervix cancer are treated by radiotherapy. Overall,
more than 50% are cured. Approximately half of those patients not cured have current cancer
in the irradiated volume. Higher doses of radiation would be expected to cure more patients.
To give high doses of radiation safely, the investigators need to know very precisely where
the cancer is and then they can use new technology available at the Cross Cancer Institute
(tomotherapy) to target the cancer precisely, giving higher doses to the cancerous tissues
and lower doses to the non-cancerous tissues.
This study of ten patients with cervical cancer will investigate the added value of MRI
scanning on precise tumor definition to facilitate more accurate radiotherapy treatment
planning. For this study, patients will be treated in the conventional way with conventional
doses. The investigators hope that treatment for future patients will be planned with MRI
data and that they will be treated to higher doses of tomotherapy.
Rationale/Background:
For a long time diagnostic imaging has been used in planning radiation treatment for the
carcinoma of the cervix, although it is not the essential part of FIGO staging work up. In
the past, treatment planning was based on examination under anesthesia (EUA) findings and
standard portals were used. Various studies have shown high risks of geographical miss
and/or inappropriate tumor coverage (up to >70%) with the use of standard portals, which was
related to poor local control. Increasingly, diagnostic/planning CT and MRI imaging are used
to plan radiation treatment.
Most patients with invasive carcinoma of the cervix, who are not candidates for radical
hysterectomy, are treated by radiotherapy, often with concomitant chemotherapy with a
curative intent. Amongst those patients, where cure is not achieved, there are a significant
proportion who fail first or only in the pelvis. Higher doses of radiation would be expected
to reduce this risk. With conventional radiotherapy, higher doses of radiation result in a
higher rate of complications. New technology available at the Cross Cancer Institute
(tomotherapy + intensity modulated radiation therapy [IMRT]) would be expected to permit
higher doses of radiation to be delivered but avoid the increased risk of complications.
Accurate definition of clinical target volume, composed of the cervix, uterus, gross primary
tumor and the regional lymphatic drainage is required for accurate treatment planning. The
MRI imaging is expected to be valuable in this regard. Demonstrating this is the immediate
aim of this study. The investigators' long term aim will be to replace conventional external
beam radiotherapy with helical tomotherapy. They expect to be able to apply increasing doses
of radiation to the GTV + CTV and monitor short-term treatment effects with biological
imaging, principally magnetic resonance spectroscopy (MRS). Eventually the investigators
hope to be able to individualize radiation doses based in part on biological imaging, before
and during treatment.
In their center the investigators routinely perform diagnostic and planning CT scans of
almost all Ca. cervix patients before radiation treatment planning. This study will involve
one additional MRI scan of the pelvis, which will take about 30 minutes to perform; this
process has potential benefit in the treatment planning.
Studies comparing imaging modalities for diagnostic accuracy:
There are studies in which CT and MRI scans were performed preoperatively and results were
compared with surgical-pathological outcome to confirm their diagnostic accuracy in terms of
tumor detection, parametrial invasion, lymph node status and adjacent organ involvement. MRI
was consistently reported to be more accurate than CT scan in terms of tumor delineation and
normal organ localization. This is also true for a meta-analysis of 17 eligible studies.
Studies Comparing Imaging Modalities for Treatment Planning:
Not surprisingly CT planning was shown to be superior over standard field technique for
external beam radiation therapy (EBRT) and brachytherapy planning for ca cervix patients.
There was less chance of geographical miss by using an imaging modality for planning.
Studies comparing MRI and CT for treatment planning showed that MRI led to significant
changes in field borders.
Image Fusion:
Harms W et al from Germany studied the fusion of CT and MRI images from sixteen patients who
were treated by interstitial (n=12) and endocavitary (n=4) brachytherapy for recurrent
cervix, head and neck, sarcoma and vulva carcinoma. They compared conventional
3D-brachytherapy planning based on CT-information alone to brachytherapy planning based on
fused CT and MRI data. They measured the accuracy of image fusion using predefined
corresponding landmarks in the CT and MRI data. They found that an automated algorithm was
robust and reliable (mean registration error 1.8 mm, range 0.8-4.1 mm, SD 0.9 mm); tumor
visualization was difficult using CT alone; and brachytherapy treatment planning based on
fused CT and MRI data enabled better definition of target volume and critical structures as
compared to treatment planning based on CT alone.
Patients and Methods:
Ten patients with a histological diagnosis of cervix carcinoma who are to receive treatment
at the Cross Cancer Institute will be enrolled in this fusion study. They will go through
the usual investigations prior to treatment planning, including CT imaging. In addition,
patients will have an MRI of the pelvis which takes approximately about 30 minutes.
CT and MRI imaging will be fused using fusion software. Treatment planning for standard four
field box technique and tomotherapy will be done on CT images as usual and subsequently on
fused images. Tumor coverage and normal organ doses will be recorded and compared. Tumor
control probabilities and normal tissue complication probabilities will be calculated for
the different plans to facilitate objective comparisons.
Conclusion:
Most patients with invasive carcinoma of the cervix, who are not candidates for a radical
hysterectomy, are often treated by concomitant chemo-radiation with a curative intent.
Patients who cannot achieve a cure with this treatment fail first or only in the pelvis. The
higher doses of radiation would be expected to reduce this risk, which cannot be achieved
with conventional radiotherapy due to higher rates of complications. Tomotherapy based
treatment planning would be expected to obtain higher doses of radiation to be delivered but
avoid the measured risk of complications. More accurate definition of clinical target
volume, composed of the cervix, uterus, gross primary tumor and the regional lymphatic
drainage is required for accurate treatment planning. Currently the investigators are
planning on the basis of CT scan only in their center; MRI scan is consistently shown to be
superior over CT for treatment. Fusing MRI and CT images are expected to delineate
structures more accurately compared to CT alone and therefore will be valuable in accurate
treatment planning to deliver higher doses to CTV without increasing treatment related
complications.
Objectives:
1. To assess the feasibility of image fusion between MRI and CT for radiotherapy (RT)
planning in Ca. Cervix
2. To determine the added value of fused MRI and CT over CT alone for RT planning.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04067882 -
Validation of the Genetic Signature 354849 as a Prognostic Method
|
||
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Recruiting |
NCT05743517 -
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
|
N/A | |
Completed |
NCT05234112 -
Prevention and Screening Towards Elimination of Cervical Cancer
|
N/A | |
Completed |
NCT04258553 -
Thiol Disulfide Balance in Cervix Cancer
|
||
Completed |
NCT03956498 -
Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy
|
N/A | |
Active, not recruiting |
NCT04357873 -
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
|
Phase 2 | |
Completed |
NCT00379743 -
Partnership for Healthy Seniors
|
N/A | |
Completed |
NCT00509444 -
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
|
Phase 3 | |
Recruiting |
NCT06022029 -
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
|
Phase 1 | |
Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
Active, not recruiting |
NCT06452004 -
Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)
|
N/A | |
Recruiting |
NCT04651127 -
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010875 -
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
Terminated |
NCT02233387 -
PET CT With HX4 in Cervix Cancer
|
Phase 2 | |
Completed |
NCT01766284 -
Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix
|
N/A |